(VIANEWS) – XOMA Corporation (XOMA), First Foundation (FFWM), BioDelivery Sciences International (BDSI) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. XOMA Corporation (XOMA)

61.2% sales growth and 11.52% return on equity

XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific.

XOMA Corporation’s sales growth this year is expected to be 27.2% and a negative 45.7% for next year.

Year-on-year quarterly revenue growth grew by 68.8%, now sitting on 29.8M for the twelve trailing months.

Volume

Today’s last reported volume for XOMA Corporation is 18000 which is 27.65% below its average volume of 24880.

XOMA Corporation’s sales growth for the next quarter is 61.2%. The company’s growth estimates for the present quarter and the next is 72% and 61.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.52%.

Volatility

XOMA Corporation’s last day, last week, and last month’s current intraday variation average was 0.43%, 2.53%, and 1.53%, respectively.

XOMA Corporation’s highest amplitude of average volatility was 5.25% (day), 8.07% (last week), and 5.02% (last month), respectively.

XOMA Corporation’s Stock Yearly Top and Bottom Value

XOMA Corporation’s stock is valued at $20.86 at 00:22 EST, way under its 52-week high of $41.99 and above its 52-week low of $19.08.

XOMA Corporation’s Moving Average

XOMA Corporation’s value is below its 50-day moving average of $21.19 and way below its 200-day moving average of $26.05.

2. First Foundation (FFWM)

36.6% sales growth and 14.95% return on equity

First Foundation Inc., through its subsidiaries, provides personal banking, business banking, and private wealth management services in the United States.

First Foundation’s sales growth this year is expected to be 19% and 23.2% for next year.

Year-on-year quarterly revenue growth grew by 22.5%, now sitting on 291.27M for the twelve trailing months.

Volume

Today’s last reported volume for First Foundation is 502606 which is 116.81% above its average volume of 231809.

First Foundation’s sales growth for the next quarter is 36.6%. The company’s growth estimates for the present quarter and the next is a negative 30% and negative 0%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.95%.

Volatility

First Foundation’s last day, last week, and last month’s current intraday variation average was 2.91%, 1.31%, and 1.19%, respectively.

First Foundation’s highest amplitude of average volatility was 2.59% (day), 3.39% (last week), and 3.08% (last month), respectively.

First Foundation’s Stock Yearly Top and Bottom Value

First Foundation’s stock is valued at $26.55 at 00:22 EST, under its 52-week high of $29.41 and way higher than its 52-week low of $20.30.

First Foundation’s Moving Average

First Foundation’s value is higher than its 50-day moving average of $26.05 and higher than its 200-day moving average of $25.32.

3. BioDelivery Sciences International (BDSI)

20.1% sales growth and 28.51% return on equity

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally.

BioDelivery Sciences International’s sales growth this year is expected to be 5.7% and 25.8% for next year.

Year-on-year quarterly revenue growth grew by 4.2%, now sitting on 165.72M for the twelve trailing months.

Volume

Today’s last reported volume for BioDelivery Sciences International is 2469390 which is 16.43% below its average volume of 2954950.

BioDelivery Sciences International’s sales growth for the next quarter is 20.1%. The company’s growth estimates for the current quarter and the next is a negative 90% and 100%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.51%.

Volatility

BioDelivery Sciences International’s last day, last week, and last month’s current intraday variation average was 0.36%, 0.22%, and 3.20%, respectively.

BioDelivery Sciences International’s highest amplitude of average volatility was 0.36% (day), 0.47% (last week), and 2.29% (last month), respectively.

BioDelivery Sciences International’s Stock Yearly Top and Bottom Value

BioDelivery Sciences International’s stock is valued at $5.55 at 00:22 EST, under its 52-week high of $5.58 and way higher than its 52-week low of $2.50.

BioDelivery Sciences International’s Moving Average

BioDelivery Sciences International’s value is way higher than its 50-day moving average of $3.70 and way higher than its 200-day moving average of $3.64.

4. Evercore Partners (EVR)

16.7% sales growth and 56.93% return on equity

Evercore Inc., together with its subsidiaries, operates as an independent investment banking advisory firm in the United States, Europe, Latin America, and internationally.

Evercore Partners’s sales growth this year is expected to be 31.9% and a negative 4.3% for next year.

Year-on-year quarterly revenue growth grew by 105.3%, now sitting on 3.13B for the twelve trailing months.

Volume

Today’s last reported volume for Evercore Partners is 318355 which is 35.44% below its average volume of 493178.

Evercore Partners’s sales growth for the next quarter is 16.7%. The company’s growth estimates for the ongoing quarter and the next is a negative 21.5% and negative -6.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 56.93%.

Volatility

Evercore Partners’s last day, last week, and last month’s current intraday variation average was 2.43%, 1.61%, and 1.99%, respectively.

Evercore Partners’s highest amplitude of average volatility was 3.75% (day), 2.75% (last week), and 4.31% (last month), respectively.

Evercore Partners’s Stock Yearly Top and Bottom Value

Evercore Partners’s stock is valued at $119.45 at 00:22 EST, way under its 52-week high of $164.63 and higher than its 52-week low of $111.51.

Evercore Partners’s Moving Average

Evercore Partners’s worth is below its 50-day moving average of $130.34 and way under its 200-day moving average of $138.66.

5. Funko (FNKO)

8.6% sales growth and 19.31% return on equity

Funko, Inc., a pop culture consumer products company, designs, sources, and distributes licensed pop culture products in the United States, Europe, and internationally.

Funko’s sales growth this year is expected to be 48% and 7.5% for next year.

Year-on-year quarterly revenue growth grew by 40%, now sitting on 919.53M for the twelve trailing months.

Volume

Today’s last reported volume for Funko is 4874880 which is 1108.06% above its average volume of 403528.

Funko’s sales growth for the next quarter is 8.6%. The company’s growth estimates for the ongoing quarter and the next is a negative 17.2% and negative -4.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.31%.

Volatility

Funko’s last day, last week, and last month’s current intraday variation average was 9.55%, 3.93%, and 2.58%, respectively.

Funko’s highest amplitude of average volatility was 9.56% (day), 5.48% (last week), and 4.38% (last month), respectively.

Funko’s Stock Yearly Top and Bottom Value

Funko’s stock is valued at $19.50 at 00:22 EST, way under its 52-week high of $27.20 and way above its 52-week low of $13.45.

Funko’s Moving Average

Funko’s worth is above its 50-day moving average of $17.74 and higher than its 200-day moving average of $18.91.

6. Alexion Pharmaceuticals (ALXN)

7.4% sales growth and 4.43% return on equity

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products.

Alexion Pharmaceuticals’s sales growth this year is expected to be 10.6% and 7% for next year.

Year-on-year quarterly revenue growth grew by 13.3%, now sitting on 6.26B for the twelve trailing months.

Alexion Pharmaceuticals’s sales growth for the next quarter is 7.4%. The company’s growth estimates for the ongoing quarter and the next is 7.1% and 4.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.43%.

Alexion Pharmaceuticals’s Stock Yearly Top and Bottom Value

Alexion Pharmaceuticals’s stock is valued at $0.00 at 00:22 EST, under its 52-week low of $99.91.

Alexion Pharmaceuticals’s Moving Average

Alexion Pharmaceuticals’s value is below its 50-day moving average of $182.75 and under its 200-day moving average of $165.77.

LEAVE A REPLY

Please enter your comment!
Please enter your name here